相关实验视频
Updated: Jul 19, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
416
激活诱导性T细胞辅助刺激器单独产生抗瘤活性,并与抗PD-1检查点阻塞相结合,产生抗瘤活性
Sapna Yadavilli1, Jeremy D Waight1, Sara Brett2
1GSK, Collegeville, Pennsylvania.
Cancer research communications
|August 18, 2023
概括
用费拉迪利马布单独或与PD-1阻断一起刺激诱导性T细胞成本刺激器 (ICOS),显示出抗瘤潜力. 这种方法激活T细胞,并在临床前模型和先进癌症早期患者研究中证明有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对共刺激受体的单克隆抗体 (mAbs) 旨在增强抗癌免疫力.
- 尽管有兴趣,但将共刺激受体信号的临床前成功转化为临床益处仍然是一个挑战.
- 诱导性T细胞辅助刺激器 (ICOS) 对于有效的T细胞反应和抗瘤免疫是至关重要的.
研究的目的:
- 评估新型抗ICOS mAb的抗瘤潜力,即诱导ICOS信号的费拉迪利马布.
- 评估费拉迪利马布作为单一疗法和与PD-1阻断药物结合的疗效.
- 介绍一项第一阶段临床试验的初步临床数据,该试验在先进的固体瘤中研究了费拉迪利马布.
主要方法:
- 在非临床模型 (老鼠和人性化的瘤) 中使用了一种新的临床阶段抗ICOS IgG4 mAb (feladilimab).
- 评估了费拉迪利马布诱导ICOS信号和刺激抗瘤T细胞的能力.
- 在先进的固体瘤中进行了首次人体I期临床试验 (INDUCE-1),评估在先进的固体瘤中配合或不配合pembrolizumab的feladilimab.
主要成果:
- 在各种癌症中表现出一致的ICOS表达,诱导刺激抗瘤T细胞.
- 表明费拉迪利马布单独或与PD-1抑制剂结合,在临床前模型中诱导了显著的抗瘤活性.
- 介绍了第一阶段试验中的病例研究,表明在患有晚期固体瘤的患者中初步临床益处.
结论:
- 用费拉迪利马布进行抗体介导的ICOS辅助刺激显示出癌症治疗的前景.
- 结合治疗与PD-1阻断可能会增强抗瘤反应.
- 通过随机试验进行进一步验证是必要的,以确认临床疗效和确定最佳患者群体.
相关概念视频
Tumor Immunotherapy
556
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
556
T Cell Activation and Clonal Selection
806
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
806
Cytotoxic T Cells-mediated Immune Response
965
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
965
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K

